Severe aplastic anemia in a patient with rheumatoid arthritis after introduction of etanercept

• Authors: Yoshiro Horai , Tomoya Miyamura , Karin Shimada , Motoko Ishida , Soichiro Takahama , Rumi Minami , Masahiro Yamamoto , Eiichi Suematsu
• Languages of publication: EN

Abstracts

EN

A 73-year-old female, diagnosed with rheumatoid arthritis (RA), complicated with severe levels of joint destruction, started etanercept (ETN) because of high persistent RA disease activity. Although her articular symptoms dramatically improved, she developed marked pancytopenia after the introduction of ETN. Bone marrow aspirate specimen revealed hypocellular marrow in three hematopoietic series without atypical findings, which was compatible with aplastic anemia (AA). This is a rare case of severe pancytopenia due to AA presumably induced by ETN.

Keywords

EN

Aplastic anemia; Rheumatoid arthritis; Etanercept

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2012
• Volume: 7
• Issue: 5
• Pages: 650-654

Dates

published

1 - 10 - 2012

online

28 - 7 - 2012

Contributors

author

Yoshiro Horai

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Tomoya Miyamura

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Karin Shimada

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Motoko Ishida

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Soichiro Takahama

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Rumi Minami

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Masahiro Yamamoto

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

author

Eiichi Suematsu

• Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital, Organization Kyushu Medical Center, 1-8-1 Jigyohama Chuo-ku, Fukuoka, 810-8563, Japan

References

• [1] van der Heijde D, Klareskog L, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum, 2006, 54: 1063–1074 http://dx.doi.org/10.1002/art.21655[Crossref]
• [2] Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis, 2010, 13: 12–26 http://dx.doi.org/10.1111/j.1756-185X.2009.01457.x[Crossref]
• [3] Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum, 2009, 61: 305–312 http://dx.doi.org/10.1002/art.24283[Crossref]
• [4] Jurisic V, Bogdanovic G, Kojic V, Jakimov D, Srdic T. Effect of TNF-alpha on Raji cells at different cellular levels estimated by various methods. Ann Hematol. 2006, 85, 86–94 http://dx.doi.org/10.1007/s00277-005-0010-3[Crossref]
• [5] Miyasaka N, Takeuchi T, Eguchi K. Guidelines for the proper use of etanercept in Japan. Mod Rheumatol, 2006, 16: 63–67 http://dx.doi.org/10.1007/s10165-006-0457-7[Crossref]
• [6] Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. J Rheumatol, 2009, 36: 898–906 http://dx.doi.org/10.3899/jrheum.080791[Crossref][WoS]
• [7] Takeuchi T, Amano K. Etanercept (in Japanese). Nippon Rinsho, 2002, 60: 2390–2396 [PubMed]
• [8] Kaushik P, Rahmani M, Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis. Ann Pharmacother, 2011, 45:e62 http://dx.doi.org/10.1345/aph.1Q492[Crossref]
• [9] Baumelou E, Guiguet M, Mary JY. Epidemiology of aplastic anemia in France: a case-control study. I. Medical history and medication use. The French Cooperative Group for Epidemiological Study of Aplastic Anemia. Blood, 1993, 81:1471–1478
• [10] Pathare SK, Heycock C, Hamilton J. TNFalpha blocker-induced thrombocytopenia. Rheumatology (Oxford), 2006, 45:1313–1314 http://dx.doi.org/10.1093/rheumatology/kel204[Crossref]
• [11] Jurisic V, Terzic T, Pavlovic S, Colovic N, Colovic M. Elevated TNF-alpha and LDH without parathormone disturbance is associated with diffuse osteolytic lesions in leukemic transformation of myelofibrosis. Pathol Res Pract. 2008, 204, 129–132 http://dx.doi.org/10.1016/j.prp.2007.09.001[Crossref][WoS]
• [12] Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol, 2003, 71: 396–398 http://dx.doi.org/10.1034/j.1600-0609.2003.00115.x[Crossref]
• [13] Balandraud N, Guis S, Meynard JB, Auger I, Roudier J, Roudier C. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. Arthritis Rheum, 2007, 57: 762–767 http://dx.doi.org/10.1002/art.22783[Crossref]
• [14] Komatsuda A, Wakui H, Nimura T, Sawada K. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Mod Rheumatol, 2008, 18, 315–318 http://dx.doi.org/10.1007/s10165-008-0053-0[Crossref][WoS]
• [15] Ueda M, Tateishi T, Shigeto H, Yamasaki R, Ohyagi Y, Kira J. A case of acute disseminated encephalomyelitis associated with Epstein-Barr virus reactivation during infliximab therapy (in Japanese). Rinsho Shinkeigaku, 2010, 50: 461–466 http://dx.doi.org/10.5692/clinicalneurol.50.461[Crossref]
• [16] Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP Jr. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood, 1997, 89:256–260
• [17] Bowman SJ, Sivakumaran M, Snowden N, et al. The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty’s syndrome. Arthritis Rheum. 1994, 37, 1326–1330 http://dx.doi.org/10.1002/art.1780370909[Crossref]
• [18] Hart DN, Baker BW, Inglis MJ, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood, 1992, 79: 2116–2123 [PubMed]
• [19] Kim TH, Choi SJ, Lee YH, Song GG, Ji JD. Soluble triggering receptor expressed on myeloid cells-1 as a new therapeutic molecule in rheumatoid arthritis. Med Hypotheses. 2012, 78, 270–272 http://dx.doi.org/10.1016/j.mehy.2011.10.042[WoS][Crossref]

Identifiers

DOI

10.2478/s11536-012-0037-5